Drug Trial Radar · NCT06780826
A Study on the Efficacy of Atezolizumab Combined with Chemotherapy
Last checked: Nov 20, 2026Latest source record: Jan 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,430
Planned (sponsor's estimate)
Start
Aug 28, 2024
Primary completion
Jun 30, 2025
Study completion Sep 30, 2025
Sponsor
- Lead sponsor
- Shanghai Pulmonary Hospital, Shanghai, ChinaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 17, 2025
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter phase III simulated RCT study aimed to compare the efficacy and safety of atezolizumab combined with chemotherapy versus placebo combined with chemotherapy in small cell lung cancer.
Conditions
- Lung Cancer, Small Cell
Interventions
AtezolizumabDrug
Atezolizumab, 1200 mg intravenous infusion, 21 days per cycle
EtoposideDrug
Etoposide,intravenous infusion, 100mg/m,21 days per cycle
CarboplatinDrug
carboplatin,intravenous infusion, AUC=5, 21 days per cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- progression free survivalTime frame: 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Pulmonary Hospital
Shanghai, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.